|

Trastuzumab (Herceptin) Clinical Trials

2 actively recruiting trials across 1 location

Pipeline

Phase 2: 1Phase 3: 1

Top Sponsors

  • Institut Curie1
  • Alliance for Clinical Trials in Oncology1

Indications

  • Breast Cancer2
  • Cancer2
  • Unresectable Breast Cancer1
  • Early Stage Breast Carcinoma1
  • Metastatic Breast Cancer ( HER2 Negative)1

Other1 trial

Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer
Phase 2

Phoenix, Arizona1 trial

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

Cancer Center at Saint Joseph's

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.